MRNA Jun 2024 210.000 put
| Previous close | 74.00 |
| Open | 74.00 |
| Bid | 87.55 |
| Ask | 92.15 |
| Strike | 210.00 |
| Expiry date | 2024-06-21 |
| Day's range | 74.00 - 77.39 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
- Reuters
US FDA pushes decision on Moderna's RSV vaccine to end of this month
The U.S. Food and Drug Administration has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine by more than two weeks to the end of this month due to some "administrative constraints", the company said on Friday. The FDA's move prolongs the wait for Moderna's second approved product, but the company said it remains on track to be reviewed by a panel of advisers at the U.S. Centers for Disease Control and Prevention (CDC) on June 26 and 27. The CDC panel is expected to vote on recommendations for the vaccine's use and the intended population at the meeting, and success there is necessary for commercial launch.
- Bloomberg
Moderna's Promise of mRNA Undercut by New RSV Vaccine
Moderna's second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Gerry Smith reports on Bloomberg Television.
Simply Wall St.Positive week for Moderna, Inc. (NASDAQ:MRNA) institutional investors who lost 6.8% over the past year
Key Insights Significantly high institutional ownership implies Moderna's stock price is sensitive to their trading...
